Source: Junction News Client
During the National Two Sessions this year, Junction News launched a series of short video reports "Amazing Innovation". The protagonist of this video is Zi Xiaoyuan, Senior Vice President of New Geyuan Biotechnology Co., Ltd. Let us listen to him tell the story of "decoding" single-cell sequencing .
My name is Zi Xiaoyuan and I am the Senior Vice President of New Geyuan Biotechnology Co., Ltd. When it comes to single-cell sequencing, many people may find it unfamiliar. This is an emerging technology that has been developed in recent years and has a great effect in scientific research and clinical applications. We have created the country's first one-stop single-cell sequencing platform.
is different from the traditional gene chip . DNA extracted from more than tens of thousands of cells or RNA is sequenced to get the average value. Single cell sequencing can analyze the genome and its expression regulation characteristics at the level of individual cells, and can more fully grasp the functions of cells. For example, during the development of an individual, from the fertilized egg to the individual, we can observe what changes have taken place in each cell through single-cell sequencing. For example, in clinical treatment, why some drugs are effective for some people, but for others Some people have no effect, and these differences can be concluded by single-cell sequencing.
single-cell sequencing has gone through different stages of development. At first, each single cell was sequenced sequentially, with low throughput and high cost. Beginning in 2018, we have innovatively adopted microfluidic chip technology to perform massive sequencing. Thousands of single-cell sequencing can be performed at a time, reducing costs and shortening the time period, which lays a good foundation for clinical single-cell sequencing. Foundation.
In addition to massive sequencing, we also focus on overcoming the technical bottleneck of single-cell sequencing. First of all, in terms of tissue processing and transportation, the experiment requires a high degree of freshness of the sample. In the past, in order to ensure the vitality of the tissue, the experimenter was required to bring the instrument to the door. The tissue preservation solution we invented can maintain tissue viability for 72 hours at 2-8 degrees Celsius. Samples from all over the country can be placed in the preservation solution and sent to our laboratory cold chain for testing.Secondly, the traditional single-cell sequencing has a long time period and a cumbersome process. We use automated instruments to capture single cells within one hour, which greatly shortens the single-cell sequencing cycle. "Data analysis" is the bottleneck of single-cell sequencing technology. We have built an automated analysis process and built a single-cell database. Currently, we have collected about 35 million single-cell data. Such accumulation will help future drug development and targets. Treatment etc.
This year is our third year in Jiangsu. We only set up two companies in China, one is located in the Biomedicine Valley of Nanjing Jiangbei New District, and the other is located in the Span3span Suzhou Industrial Park. When we first started our business in 2018, we felt that Jiangsu was our best choice. Looking back now, this decision is still very wise. Jiangsu has built a development platform for the biomedical industry. Whether it is the Biomedical Valley in Nanjing Jiangbei New District or the Suzhou Bio-Nano Park, a large number of biomedical companies have gathered. We can quickly find “organizations” to cooperate and win-win. In addition, the gathering of universities in Jiangsu, a strong atmosphere of valuing talents, and a forceful policy of attracting talents provide talent support for enterprise development and help us usher in a "good start".
The park also provides us with a series of services such as premises, loans, tax reduction and exemption, and "escorts" our entrepreneurial road. With such support, we can also be at ease, concentrate all our efforts, and contribute our own strength to China's "big health" cause. Planning: Ren Songyun, Kong Dexin Coordinating: Tang Cheng Copywriter: Zhou Xian Camera: Gao Xin Later: Gao Xin Packaging: Tao Rong
.
